Cover Image
Market Research Report

Gallbladder Cancer - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 360915
Published Content info 527 Pages
Delivery time: 1-2 business days
Price
Back to Top
Gallbladder Cancer - Pipeline Review, H2 2019
Published: December 27, 2019 Content info: 527 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2019, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 19, 14 and 6 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11717IDB

Table of Contents

  • Introduction
  • Gallbladder Cancer - Overview
  • Gallbladder Cancer - Therapeutics Development
  • Gallbladder Cancer - Therapeutics Assessment
  • Gallbladder Cancer - Companies Involved in Therapeutics Development
  • Gallbladder Cancer - Drug Profiles
  • Gallbladder Cancer - Dormant Projects
  • Gallbladder Cancer - Discontinued Products
  • Gallbladder Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Gallbladder Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Gallbladder Cancer - Pipeline by 4SC AG, H2 2019
  • Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
  • Gallbladder Cancer - Pipeline by Almac Discovery Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Alphamab Oncology, H2 2019
  • Gallbladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
  • Gallbladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Apollomics Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by AstraZeneca Plc, H2 2019
  • Gallbladder Cancer - Pipeline by Bayer AG, H2 2019
  • Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Gallbladder Cancer - Pipeline by Delta-Fly Pharma Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Diverse Biotech Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Eisai Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Eli Lilly and Co, H2 2019
  • Gallbladder Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2019
  • Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Ipsen SA, H2 2019
  • Gallbladder Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Karus Therapeutics Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Lokon Pharma AB, H2 2019
  • Gallbladder Cancer - Pipeline by Merck & Co Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Mina Therapeutics Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Molecular Templates Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Novartis AG, H2 2019
  • Gallbladder Cancer - Pipeline by NuCana Plc, H2 2019
  • Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Pfizer Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Rafael Pharmaceuticals Inc, H2 2019
  • Gallbladder Cancer - Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Sinocelltech Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by SMT bio Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by TOT Biopharm Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Turning Point Therapeutics Inc, H2 2019
  • Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2019
  • Gallbladder Cancer - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
  • Gallbladder Cancer - Pipeline by Zymeworks Inc, H2 2019
  • Gallbladder Cancer - Dormant Projects, H2 2019
  • Gallbladder Cancer - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Gallbladder Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top